Diligence memo · auto-generated · as of July 2, 2026

Edenbridge Holdings LLC

Edenbridge Holdings LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Edenbridge Holdings LLC operates in Pharmaceuticals, based in NEW YORK.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Edenbridge Holdings LLC has raised $15M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $15M on 2017-01-11.

Most recent recorded round closed around 2017-01-11.

Valuation (modeled)modeled

Provath models Edenbridge Holdings LLC at approximately $524M (range $32M–$2.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.77× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era. Within the normal band (77% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 9.5 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 62% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 81% of those peers.

Closest niche peers: LP Investors, LLC, GigaGen, Inc., Vitality Biopharma, Inc., Madrigal Pharmaceuticals, Inc., Slayback Pharma Ltd Liability Co.

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.